Voyager Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M |
| Operating expenses | $172.2M | $163.3M | $128.0M | $91.7M | $111.0M |
| Cash from operations | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M |
| Capital expenditure | $2.6M | $3.5M | $3.3M | $2.5M | $1.6M |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M |
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M |
Shares outstanding 60.4M · Free float 66.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.